| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| monalizumab | nkg2-a/b-activating nk receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Cancer of Head and Neck[MeSHID:D006258] Chronic Lymphocytic Leukemia[MeSHID:D015451] |
127.3 | phase 1/2 | unknown |
| monalizumab | nkg2-a/b-activating nk receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Cancer of Head and Neck[MeSHID:D006258] Chronic Lymphocytic Leukemia[MeSHID:D015451] |
127.3 | phase 1/2 | antibody |
| click here to return to the previous page | ||||||||